STATE OF THE ART PAPER
Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state
 
More details
Hide details
1
Internal Medicine and Diabetes Clinic, Paphos, Cyprus
2
CDA College, Paphos, Cyprus
Submission date: 2020-12-26
Final revision date: 2021-02-09
Acceptance date: 2021-03-21
Publication date: 2021-04-12
 
Arch Med Sci Atheroscler Dis 2021;6(1):57–78
 
KEYWORDS
TOPICS
ABSTRACT
Empagliflozin is a SGLT2 inhibitor that has shown remarkable cardiovascular and renal activities in patients with type 2 diabetes (T2D). Preclinical and clinical studies of empagliflozin in T2D population have demonstrated significant improvements in body weight, waist circumference, insulin sensitivity, and blood pressure – effects beyond its antihyperglycaemic control. Moreover, several studies suggested that this drug possesses significant anti-inflammatory and antioxidative stress properties. This paper explores extensively the main preclinical and clinical evidence of empagliflozin administration in insulin resistance-related disorders beyond a diabetic state. It also discusses its future perspectives, as a therapeutic approach, in this high cardiovascular-risk population.
ISSN:2451-0629